Luca Licata

1.6k total citations · 1 hit paper
24 papers, 932 citations indexed

About

Luca Licata is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Luca Licata has authored 24 papers receiving a total of 932 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Luca Licata's work include Cancer Immunotherapy and Biomarkers (7 papers), Cancer Genomics and Diagnostics (7 papers) and Advanced Breast Cancer Therapies (5 papers). Luca Licata is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Cancer Genomics and Diagnostics (7 papers) and Advanced Breast Cancer Therapies (5 papers). Luca Licata collaborates with scholars based in Italy, United States and Germany. Luca Licata's co-authors include Giampaolo Bianchini, Carmine De Angelis, Luca Gianni, Giulia Viale, Giuseppe Curigliano, Judy E. Garber, Filipa Lynce, Carmen Criscitiello, Stefania Morganti and Antonio Giordano and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Luca Licata

21 papers receiving 927 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment landscape of triple-negative breast cancer — expanded options, evolving needs

2021 801 citations Giampaolo Bianchini, Carmine De Angelis et al. Nature Reviews Clinical Oncology profile →

Peers

Luca Licata

ONCOL

PRM

IMMUN

Yeuan Ting Lee Malaysia

Beilei Liu China

Ruoxi Hong China

Jean-Pierre Gillet United States

Magali Rebucci France

Rachel M. Webster United States

Guangshun Sun China

Jelena Grahovac Serbia

Hanna Dillekås Norway

Zahra Eslami‐S France

Yeuan Ting Lee Malaysia

Luca Licata

300 ×0.6

ONCOL

498 ×1.2

192 ×0.7

139 ×0.7

PRM

85 ×0.5

IMMUN

Citations per year, relative to Luca Licata Luca Licata (= 1×) peers Yeuan Ting Lee

Countries citing papers authored by Luca Licata

Since Specialization

Citations

This map shows the geographic impact of Luca Licata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Licata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Licata more than expected).

Fields of papers citing papers by Luca Licata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luca Licata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Licata. The network helps show where Luca Licata may publish in the future.

Co-authorship network of co-authors of Luca Licata

This figure shows the co-authorship network connecting the top 25 collaborators of Luca Licata. A scholar is included among the top collaborators of Luca Licata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luca Licata. Luca Licata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yeo, Winnie, Giampaolo Bianchini, Javier Cortés, et al.. (2025). Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates. Future Oncology. 21(10). 1261–1272.

Licata, Luca, Giulia Viale, Rebecca Dent, et al.. (2025). Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research. 31(18). 3916–3921.

Licata, Luca, Maria Vittoria Dieci, Carmine De Angelis, et al.. (2024). Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer. Cancer Treatment Reviews. 128. 102762–102762. 6 indexed citations

Naldini, Matteo Maria, Giulia Viale, Alessia Rognone, et al.. (2024). Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice. Frontiers in Oncology. 14. 1374547–1374547. 4 indexed citations

Licata, Luca, Rita De Sanctis, Andrea Vingiani, et al.. (2024). Real-world use of multigene signatures in early breast cancer: differences to clinical trials. Breast Cancer Research and Treatment. 205(1). 39–48. 1 indexed citations

Mariani, Marco Giovanni, Giulia Viale, Barbara Galbardi, et al.. (2024). Completion Rate and Positive Results Reporting Among Immunotherapy Trials in Breast Cancer, 2004-2023. JAMA Network Open. 7(7). e2423390–e2423390. 2 indexed citations

Morganti, Stefania, Antonio Marra, Carmine De Angelis, et al.. (2024). PARP Inhibitors for Breast Cancer Treatment. JAMA Oncology. 10(5). 658–658. 39 indexed citations

Licata, Luca, Deborah Cosentini, Rita De Sanctis, et al.. (2023). Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group. Frontiers in Oncology. 13. 1081885–1081885. 2 indexed citations

Licata, Luca, Barbara Galbardi, Matteo Dugo, et al.. (2023). Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy. British Journal of Cancer. 129(12). 2025–2033. 6 indexed citations

10.

Licata, Luca, Giulia Viale, Stefania Zambelli, et al.. (2023). 2090P Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice. Annals of Oncology. 34. S1098–S1098.

11.

Licata, Luca, Marco Giovanni Mariani, Federico Rossari, et al.. (2023). Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer. The Breast. 69. 330–341. 9 indexed citations

12.

Callari, Maurizio, Matteo Dugo, Barbara Galbardi, et al.. (2022). Abstract PD10-09: Comparison of early modulation of biological pathways and immune microenvironment by anthracyclines- or taxane-based treatment. Cancer Research. 82(4_Supplement). PD10–9. 2 indexed citations

13.

Bianchini, Giampaolo, Carmine De Angelis, Luca Licata, & Luca Gianni. (2021). Treatment landscape of triple-negative breast cancer — expanded options, evolving needs. Nature Reviews Clinical Oncology. 19(2). 91–113. 801 indexed citations breakdown →

14.

Bianchini, Giampaolo, Matteo Dugo, Balázs Győrffy, et al.. (2021). ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.. Journal of Clinical Oncology. 39(15_suppl). 555–555. 1 indexed citations

15.

Bianchini, Giampaolo, Chanel E. Smart, Mauro Mansutti, et al.. (2020). Modulation by treatment of tumor infiltrating lymphocytes (TILs) and PDL1 expression in triple-negative breast cancer in the ETNA trial.. Journal of Clinical Oncology. 38(15_suppl). 555–555. 3 indexed citations

16.

Palumbo, Raffaella, Federico Sottotetti, Erica Quaquarini, et al.. (2019). Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience. Therapeutic Advances in Medical Oncology. 11. 3862448904–3862448904. 12 indexed citations

17.

Palumbo, Raffaella, Luca Licata, Federico Sottotetti, et al.. (2018). Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series. Oncology Research and Treatment. 41(1-2). 8–13. 1 indexed citations

18.

D’Ambrosio, Daniela, et al.. (2018). Monitoring response of advanced Merkel cell carcinoma to Avelumab with 18F-FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 46(5). 1197–1198. 6 indexed citations

19.

Quaquarini, Erica, Federico Sottotetti, Anna Gambaro, et al.. (2017). Comorbidity scores as predictive tools for nivolumab toxicity in patients with advanced non small cell lung cancer (NSCLC): preliminary results of a prospective multicenter study. Annals of Oncology. 28. vi60–vi60. 1 indexed citations

20.

Gambaro, Anna, Federico Sottotetti, Luca Licata, et al.. (2016). Patterns of treatment and outcome of fulvestrant 500mg in postmenopausal women with hormone-positive (HR+)/Her2-negative (HER2-) metastatic breast cancer (MBC): a real life multicenter Italian experience. Annals of Oncology. 27. vi82–vi82. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact